News ImmuneRegen NewsImmuneRegen BioSciences Prepares for Department of Health and Human Services RFP for Therapeutics to Treat Acute Radiation SyndromeJune 21, 2005SCOTTSDALE, AZ – Research and development bio-pharmaceutical company, ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO), announced today that it is preparing to respond to the Department of Health and Human Services (DHHS) Request for Proposals on the general topic of Acute Radiation Sickness (ARS). The DHHS recently announced they anticipate releasing a draft Request for Proposals for industry comment by July 2005. ImmuneRegen plans to include the latest findings on the efficacy of Radilex™ in treating the negative effects of toxic radiation exposure in their response. "Our response will show that after seven rounds of animal testing for ARS using lethal dosages of radiation and reaching a 50% survival rate, there is little doubt that Radilex™ has incredible potential to save lives in the event of a terrorist attack,” states co-founder and CEO Michael Wilhelm. "We believe we will show our methods of action do not simply neutralize the attacking agent, but actually increase immune system activity, thereby allowing the body's own immune system architecture to repair itself.” Once issued, ImmuneRegen will file a formal response to the RFP respective to its compound Radilex™ currently in development for treating the negative effects of toxic radiation exposure, including ARS. Recent testing of Radilex™ using Total Body Irradiation (TBI) showed a 50% survival rate among irradiated mice treated with Radilex™ Post Lethal Exposure (PLE). This RFP is another step under the U.S. Government’s Project BioShield to uncover effective new treatments for ARS. Project BioShield is legislation enacted by Congress and signed into law by the President to provide incentives and dedicated funds to encourage private industry to develop original medical technology to meet the Nation's bio-terrorism defense needs. Under a provision known as an Emergency Use Authorization, the RFP data will be used by DHHS in the procurement of new medical counter-measures for the Strategic National Stockpile, in advance of formal FDA approval. ImmuneRegen BioSciences has begun preparations to produce the compound on a large scale should such potential purchases of Radilex™ occur. The company's current production of Radilex™ is manufactured under GMP standards. About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|